Wegovy Pharmacokinetics (ADME): How Semaglutide 2.4 mg Is Absorbed, Distributed, Metabolized, and Excreted

What Wegovy Is and Why Pharmacokinetics Matter

Wegovy is a once-weekly subcutaneous GLP-1 receptor agonist approved by the FDA in June 2021 for chronic weight management in adults with a BMI ≥30 kg/m² or ≥27 kg/m² with at least one weight-related comorbidity. FDA approval details are listed on the agency's NDA 215256 page. Semaglutide is a modified GLP-1 analogue sharing about 94% sequence homology with native human GLP-1 [1].

Understanding the ADME profile of semaglutide 2.4 mg is not just academic. Prescribers need this data to counsel patients on injection timing, explain why dose escalation takes months, and anticipate interactions when co-prescribing oral medications with narrow absorption windows. Patients who understand the 7-day half-life are also more likely to adhere to the once-weekly schedule instead of doubling up after a missed dose.

STEP-1 (N=1,961) showed that semaglutide 2.4 mg produced 14.9% mean body-weight loss at 68 weeks versus 2.4% with placebo [2]. That magnitude of effect depends entirely on maintaining therapeutic plasma concentrations, which the pharmacokinetic profile is engineered to support.

Absorption: How Semaglutide Moves from Injection Site to Bloodstream

Subcutaneous semaglutide is absorbed slowly from the injection depot into the systemic circulation. Peak plasma concentrations are reached 24 to 72 hours after injection, with a median Tmax of approximately 1 to 3 days [1]. The FDA prescribing information for Wegovy confirms this range across the approved dose strengths (0.25 mg through 2.4 mg) [3].

Absolute Bioavailability

The absolute subcutaneous bioavailability of semaglutide is approximately 89%, as established in a crossover pharmacokinetic study [4]. This high bioavailability reflects slow lymphatic uptake from the injection depot combined with minimal first-pass hepatic extraction, since the drug bypasses the portal circulation entirely when injected subcutaneously.

Injection Site and Rotation

Clinical pharmacokinetic studies show no clinically meaningful difference in semaglutide exposure whether the drug is injected into the abdomen, thigh, or upper arm [3]. Rotating injection sites is recommended for skin tolerability rather than for absorption consistency. Injection into lipodystrophic or scarred tissue may, however, reduce local capillary density and theoretically slow absorption.

Effect of Dose Escalation on Absorption

The dose-escalation schedule (starting at 0.25 mg and increasing to 2.4 mg over 16 to 20 weeks) does not change the absorption rate constant. It changes only the amount of drug absorbed per dose. Exposure (AUC and Cmax) increases proportionally with dose across the therapeutic range, supporting once-weekly dosing throughout escalation [3].

Distribution: Where Semaglutide Goes in the Body

Once absorbed, semaglutide distributes into a relatively small apparent volume. The volume of distribution at steady state is approximately 12.5 liters, which is close to plasma volume and confirms that the drug is largely confined to the vascular compartment rather than distributing widely into peripheral tissues [1].

Albumin Binding

More than 99% of circulating semaglutide is bound to plasma albumin [1]. This tight binding serves two purposes. First, it dramatically extends the half-life by creating a large protein-bound reservoir that releases drug slowly. Second, it protects semaglutide from renal filtration, since albumin-bound drug cannot pass through the glomerulus [5].

The C-18 fatty diacid chain attached to semaglutide's lysine residue at position 26 is specifically engineered to enhance albumin affinity, distinguishing semaglutide from shorter-acting GLP-1 receptor agonists such as exenatide and liraglutide, which carry shorter fatty acid modifications [6].

CNS Penetration and Appetite Regulation

GLP-1 receptors exist in the hypothalamus and brainstem, and central receptor activation is considered a key mechanism behind semaglutide's appetite-suppressive effects [7]. Despite the high degree of albumin binding, semaglutide reaches the hypothalamic arcuate nucleus and area postrema via circumventricular organs that lack a conventional blood-brain barrier [8]. This explains the appetite suppression and nausea that patients report even though peripheral volume of distribution is small.

Mechanism of Action: What Happens at the GLP-1 Receptor

Semaglutide binds to and activates the GLP-1 receptor, a class B G-protein-coupled receptor expressed in the pancreas, gut, brain, heart, and kidneys [7]. Receptor activation raises intracellular cyclic AMP, which drives the downstream effects relevant to weight management and glycemic control.

Pancreatic Effects

In the pancreas, GLP-1 receptor activation stimulates glucose-dependent insulin secretion and suppresses glucagon release [9]. The glucose-dependent mechanism means insulin is only released when plasma glucose is elevated, which is why semaglutide carries a low intrinsic risk of hypoglycemia when used without sulfonylureas or insulin [3].

Gastric Emptying

Semaglutide slows gastric emptying, most prominently during the first weeks of treatment [10]. This slowing contributes to early satiety and post-meal glucose flattening. A pharmacodynamic study using 13C-octanoic acid breath testing showed that gastric emptying half-time increases by roughly 38% during the first 12 weeks of semaglutide but partially normalizes by week 26, even as the drug's plasma concentration holds steady [10]. This tachyphylaxis of the gastric-emptying effect means the drug's weight-loss efficacy is maintained long-term primarily through central appetite suppression rather than delayed stomach emptying.

Hypothalamic Appetite Suppression

Activation of GLP-1 receptors in the arcuate nucleus reduces neuropeptide Y and agouti-related peptide signaling while increasing pro-opiomelanocortin activity, shifting the energy-balance set point downward [8]. A 2021 review in Obesity Reviews estimated that roughly 60% of semaglutide's weight-reducing effect is mediated centrally [11].

The clinical implication: nausea, which peaks in the first 4 to 8 weeks of treatment, arises partly from activation of area postrema GLP-1 receptors, not from direct gastric irritation. Slow dose escalation reduces this by allowing receptor desensitization before full doses are reached [3].

Steady State: When Does Wegovy Reach Full Therapeutic Effect?

Steady-state plasma concentrations are reached after approximately 4 to 5 weeks of once-weekly dosing, corresponding to roughly 4 to 5 half-lives [1]. At the 2.4 mg maintenance dose, mean steady-state AUC is approximately 2,640 nmol·h/L, and mean Cmax is approximately 166 nmol/L [3].

Because steady state requires 4 to 5 weeks at each dose level, the 16-to-20-week escalation schedule means patients do not reach therapeutic steady-state concentrations at the 2.4 mg dose until approximately week 20 to 24. This timeline explains why the most substantial weight loss in STEP-1 occurred between weeks 20 and 68 rather than in the first month [2].

Clinicians should communicate this timeline explicitly. Patients expecting rapid results in week 2 may discontinue prematurely before therapeutic concentrations are established.

Metabolism: How the Body Breaks Down Semaglutide

Semaglutide is not metabolized by cytochrome P450 enzymes. This is one of the most clinically significant pharmacokinetic features of the drug, because it means semaglutide has a very low potential for CYP-mediated drug-drug interactions [3].

Proteolytic Cleavage

The primary metabolic pathway is sequential proteolytic cleavage of the peptide backbone by endopeptidases and dipeptidyl peptidase IV (DPP-4), with additional contributions from neutral endopeptidases [1]. The C-18 fatty diacid linker also undergoes oxidation via beta-oxidation pathways, but this accounts for a minor fraction of total clearance.

Structural Modifications That Resist Degradation

Native GLP-1 has a plasma half-life of only 1 to 2 minutes due to rapid DPP-4 cleavage at the alanine-2 position [6]. Semaglutide resists this by substituting alpha-aminoisobutyric acid at position 8, blocking the DPP-4 cleavage site, and by adding the C-18 fatty diacid chain at lysine-26 to promote albumin binding [1]. These two modifications, combined with a backbone Aib substitution, extend half-life from minutes to approximately 168 hours.

A PubMed-indexed pharmacology review confirmed that the Aib-8 substitution alone reduces DPP-4 cleavage by greater than 95% compared with native GLP-1 [6].

Excretion: How Semaglutide Leaves the Body

Semaglutide and its metabolites are eliminated through both urine and feces. After radiolabeled semaglutide administration, approximately 65% of radioactivity was recovered in urine and 24% in feces over a collection period spanning multiple weeks [3]. The remainder was unaccounted for, consistent with incomplete collection windows for a drug with a 7-day half-life.

Renal Considerations

Because semaglutide is >99% albumin-bound, intact drug does not pass the glomerular filter. What appears in urine is predominantly small peptide metabolites produced after proteolytic breakdown [5]. The FDA label states no dose adjustment is needed for any degree of renal impairment, including patients on dialysis, which was confirmed in a dedicated renal pharmacokinetic study (N=88) showing no clinically relevant increase in AUC across renal function strata [12].

This renal profile contrasts with exenatide, which requires dose adjustment when creatinine clearance falls below 30 mL/min and is contraindicated below 15 mL/min [13].

Hepatic Considerations

Hepatic impairment does not meaningfully alter semaglutide pharmacokinetics. A dedicated study in subjects with mild, moderate, and severe hepatic impairment (Child-Pugh A, B, and C) found no clinically relevant differences in AUC or Cmax versus subjects with normal hepatic function [3]. No dose adjustment is required for hepatic impairment.

Drug-Drug Interactions: What Changes With Co-Administration

Because semaglutide bypasses CYP450 metabolism entirely, pharmacokinetic drug-drug interactions are rare [3]. The interaction signal that does exist is indirect, mediated through delayed gastric emptying.

Oral Medications With Narrow Absorption Windows

Slowed gastric emptying can delay the rate (Cmax) but not necessarily the extent (AUC) of absorption for oral drugs. Clinically relevant candidates include:

• Levothyroxine: A population PK analysis found a modest reduction in levothyroxine Cmax with semaglutide co-administration; TSH monitoring at 6 to 8 weeks after starting semaglutide is prudent [14].
• Oral contraceptives: The FDA label for oral semaglutide (Rybelsus) flags a possible decrease in ethinylestradiol exposure; the same principle applies to subcutaneous semaglutide given sufficient gastric-emptying inhibition [3].
• Warfarin: No PK interaction was detected in dedicated studies, but INR monitoring is still recommended in the first weeks of co-administration due to any indirect absorption effects [3].

Insulin and Sulfonylureas

Co-prescription of semaglutide with insulin or sulfonylureas does not alter semaglutide's own pharmacokinetics. The interaction is pharmacodynamic: additive glucose lowering increases hypoglycemia risk [9]. The SUSTAIN-6 trial (N=3,297) and the SELECT cardiovascular outcomes trial (N=17,604) both confirmed no unexpected PK signals when semaglutide was co-administered with background diabetes and cardiovascular medications [15, 16].

Special Populations: Renal, Hepatic, Age, Weight, and Pregnancy

Body Weight

Higher body weight is associated with modestly higher semaglutide clearance [3]. A population pharmacokinetic analysis found that a 100 kg patient has approximately 20% higher clearance than a 70 kg patient, which the fixed 2.4 mg weekly dose does not fully compensate for. This may partly explain why patients with higher baseline BMI sometimes show attenuated weight-loss percentages, though the STEP-1 data showed meaningful responses across BMI categories [2].

Older Adults

Age between 18 and 87 years did not meaningfully affect semaglutide PK in a population analysis [3]. Cmax and AUC were within 10% across age groups, supporting use without age-based dose adjustment.

Pediatric Use (12 to 17 Years)

The FDA expanded Wegovy's indication to adolescents aged 12 and older in December 2022 based on the STEP TEENS trial (N=201), which showed 16.1% reduction in BMI at 68 weeks versus 0.6% with placebo [17]. PK data from STEP TEENS confirm that the exposure-response relationship in adolescents is consistent with that in adults, with no dose modification required [17].

Pregnancy and Lactation

Animal reproduction studies showed fetal harm at exposures above the human therapeutic range [3]. Wegovy is not recommended during pregnancy. Whether semaglutide is excreted in human breast milk is unknown; the molecular weight (approximately 4,113 Da) and high albumin binding suggest limited transfer, but no controlled lactation studies exist [3].

Missed Doses and Re-Dosing: Pharmacokinetic Rationale

If a dose is missed and fewer than 5 days remain until the next scheduled dose, skip the missed dose and resume the regular schedule [3]. If more than 5 days remain, the missed dose may be given as soon as possible.

The 5-day cutoff is pharmacokinetically rational: the half-life of approximately 168 hours means that at day 5 after a missed dose, plasma concentrations have fallen by roughly 50%. Administering a dose at that point and again on the regular schedule 2 days later would produce transient supra-therapeutic exposure, potentially worsening GI side effects without meaningful additional efficacy.

Comparing Semaglutide 2.4 mg PK to Other GLP-1 Receptor Agonists

| Drug | Half-life | Dosing Frequency | Bioavailability | CYP Metabolism | |---|---|---|---|---| | Semaglutide 2.4 mg (Wegovy) | ~168 h | Once weekly | ~89% SC | None | | Liraglutide 3.0 mg (Saxenda) | ~13 h | Once daily | ~55% SC | None | | Exenatide ER (Bydureon) | ~2 weeks | Once weekly | ~65% SC | None | | Tirzepatide 15 mg (Zepbound) | ~5 days | Once weekly | ~89% SC | None | | Dulaglutide 4.5 mg (Trulicity) | ~5 days | Once weekly | ~47% SC | None |

Data from FDA prescribing information for each agent [3, 13, 18, 19, 20]. Semaglutide's 89% bioavailability and 7-day half-life place it among the most pharmacokinetically favorable agents in the class for once-weekly dosing adherence.

Pharmacokinetic Drivers of the Clinical Weight-Loss Curve

The shape of the weight-loss curve in STEP-1, where most of the 14.9% mean loss accumulated between weeks 16 and 52, maps directly onto pharmacokinetic milestones [2].

• Weeks 1 to 4: Sub-therapeutic concentrations during dose escalation.
• Weeks 4 to 20: Stepwise increases through the escalation schedule, with steady state achieved at each level.
• Weeks 20 to 68: Full steady-state exposure at 2.4 mg; plateau of weight loss as a new energy-balance set point is established.

A population PK/PD model published in Clinical Pharmacokinetics (2022) confirmed that the weight-loss time course is best described by an indirect-response model where semaglutide plasma concentration drives a fractional reduction in net caloric intake, not a direct tissue effect [21]. The model predicted that >80% of the maximum weight-loss effect is captured only after 32 weeks at steady-state exposure, consistent with trial observations.

Clinical Takeaways for Prescribers

Semaglutide 2.4 mg's pharmacokinetic profile is purpose-built for once-weekly subcutaneous use. Seven key points merit emphasis:

1. Steady state requires 4 to 5 weeks per dose level; full maintenance-dose steady state is not reached until approximately week 20.
2. The >99% albumin binding drives the 7-day half-life and protects against renal clearance.
3. No CYP450 metabolism means a low drug-interaction burden overall.
4. Gastric emptying inhibition is the primary interaction mechanism for orally administered co-medications.
5. No renal or hepatic dose adjustment is needed across the full spectrum of organ impairment.
6. Body weight modestly increases clearance; the fixed 2.4 mg dose is appropriate for most patients.
7. The 5-day rule for missed doses has a direct pharmacokinetic basis in the drug's half-life.